Patrickg Lepore News Today

VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 88,000 shares, a growth of 1,157.1% from the December 15th total of 7,000 shares. Based on an average trading volume of 401,800 shares, the short-interest ratio […]

VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Free Report) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 7,000 shares, a drop of 94.4% from the November 30th total of 124,800 shares. Based on an average daily volume of 366,400 shares, the days-to-cover ratio […]

VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Rating) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 91,900 shares, a decline of 55.6% from the April 30th total of 206,800 shares. Currently, 2.9% of the shares of the company are sold short. Based on […]

VYNE Therapeutics (NASDAQ:VYNE – Get Rating) had its price target lifted by Cantor Fitzgerald from $5.00 to $9.00 in a report released on Friday morning, The Fly reports. Separately, HC Wainwright reaffirmed a buy rating and set a $28.00 target price on shares of VYNE Therapeutics in a report on Wednesday, April 19th. VYNE Therapeutics […]

VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Rating) was the recipient of a large increase in short interest in April. As of April 30th, there was short interest totalling 206,800 shares, an increase of 119.1% from the April 15th total of 94,400 shares. Based on an average daily volume of 694,700 shares, the days-to-cover ratio is […]

VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Rating) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 98,200 shares, an increase of 30.2% from the March 15th total of 75,400 shares. Based on an average daily volume of 57,200 shares, the […]

Equities research analysts expect Lannett Company, Inc. (NYSE:LCI – Get Rating) to announce $83.65 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Lannett’s earnings. The highest sales estimate is $85.00 million and the lowest is $82.30 million. Lannett reported sales of $112.37 million in the same quarter […]

Equities research analysts expect Lannett Company, Inc. (NYSE:LCI – Get Rating) to post ($0.43) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Lannett’s earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.41). Lannett reported earnings per […]

Lannett (NYSE:LCI – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports. According to Zacks, “Lannett Company manufactures and distributes high quality affordable generic medications that are the therapeutic equivalent of the brand-name pharmaceuticals. Their portfolio consists of numerous […]

Equities analysts forecast that Lannett Company, Inc. (NYSE:LCI – Get Rating) will announce earnings of ($0.43) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Lannett’s earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.41). Lannett posted earnings of […]